SPRR2A and neoplasm: NHS-muIL12 (10μg, corresponding to a dose of 5.4μg of murine IL-12 equivalents) demonstrated greater anti-tumor effects compared with rMuIL-12 (5.4μg) in 3 different syngeneic tumor models (Lewis lung carcinoma (LLC); MC38 colon carcinoma; B16 melanoma) (2-way ANOVA with Bonferroni post-test, P < 0.050) (Figure 2D–F).